Aptinyx Inc. (APTX): Price and Financial Metrics

Aptinyx Inc. (APTX): $0.12

-0.01 (-6.52%)

POWR Rating

Component Grades













APTX Stock Price Chart Interactive Chart >

Price chart for APTX

APTX Price/Volume Stats

Current price $0.12 52-week high $2.87
Prev. close $0.13 52-week low $0.12
Day low $0.12 Volume 5,780,100
Day high $0.13 Avg. volume 3,259,563
50-day MA $0.35 Dividend yield N/A
200-day MA $0.39 Market Cap 8.45M

Aptinyx Inc. (APTX) Company Bio

Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.

APTX Latest News Stream

Event/Time News Detail
Loading, please wait...

APTX Latest Social Stream

Loading social stream, please wait...

View Full APTX Social Stream

Latest APTX News From Around the Web

Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.

Bicycle (BCYC) up on Collaboration With Novartis for Conjugates

Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.

Yahoo | March 29, 2023

Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug

Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.

Yahoo | March 28, 2023

Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up

Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.

Yahoo | March 27, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Friday!

William White on InvestorPlace | March 24, 2023

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

Yahoo | March 21, 2023

Read More 'APTX' Stories Here

APTX Price Returns

1-mo -38.78%
3-mo -57.94%
6-mo -67.40%
1-year -94.71%
3-year -94.44%
5-year N/A
YTD -57.94%
2022 -89.31%
2021 -22.83%
2020 1.17%
2019 -79.32%
2018 N/A

Continue Researching APTX

Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:

Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8963 seconds.